Posted by Michael Wonder on 02 Aug 2021
Alkermes receives FDA fast track designation for nemvaleukin alfa for the treatment of mucosal melanoma
2 August 2021 - Alkermes today announced that the U.S. FDA has granted fast track designation to nemvaleukin alfa, the company's novel, investigational engineered interleukin-2 variant immunotherapy, for the treatment of mucosal melanoma.
Earlier this year, the FDA also granted orphan drug designation to nemvaleukin alfa for the treatment of mucosal melanoma.
